tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Tirzepatide is NO longer in

This rebound occurs because semaglutide masks underlying hunger signals and metabolic patterns rather than permanently rewiring them, meaning your body's natural appetite-regulation pathways remain unchanged once the drug leaves your system

Reduced potency from expired medication may mean your glucose levels are higher than expected

Journal of Nutritional Biochemistry, 22(5), 426440

Mounjaro has shown greater weight loss outcomes compared to Retatrutide in clinical trials, but both medications offer effective weight management options, with individual considerations influencing the choice between them

Chianelli, M

The possibility of taking an oral preparation would also allow patient preferences to be taken into account when deciding on what treatment to prescribe